Marieke van Vessem

Dr. Marieke van Vessem

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2019 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
MVMarieke van Vessem
Marieke van Vessem
SBSaskia L.M.A. Beeres
Saskia L.M.A. Beeres
Robert B. P. De WildeRobert B. P. De Wilde
Robert B. P. De Wilde
RVRené de Vries
René de Vries
RBRemco Berendsen
Remco Berendsen
Meindert PalmenMeindert Palmen
Meindert Palmen
Background: Vasoplegia is a severe complication which may occur after cardiac surgery, particularly in patients with heart failure. It is a result of activation of vasodilator pathways, inactivation of vasoconstrictor pathways and the resistance to vasopressors. However, the precise etiology remains unclear. The aim of the Vasoresponsiveness in patients with heart failure (VASOR) study is to objectify and characterize the altered vasoresponsiveness in patients with heart failure, before, during and after heart failure surgery and to identify the etiological factors involved. Methods: This is a prospective, observational study conducted at Leiden University Medical Center. Patients with and patients without heart failure undergoing cardiac surgery on cardiopulmonary bypass are enrolled. The study is divided in two inclusion phases. During phase 1, 18 patients with and 18 patients without heart failure are enrolled. The vascular reactivity in response to a vasoconstrictor (phenylephrine) and a vasodilator (nitroglycerin) is assessed in vivo on different timepoints. The response to phenylephrine is assessed on t1 (before induction), t2 (before induction, after start of cardiotropic drugs and/or vasopressors), t3 (after induction), t4 (15 min after cessation of cardiopulmonary bypass) and t5 (1 day post-operatively). The response to nitroglycerin is assessed on t1 and t5. Furthermore, a sample of pre-pericardial fat tissue, containing resistance arteries, is collected intraoperatively. The ex vivo vascular reactivity is assessed by constructing concentrations response curves to various vasoactive substances using isolated resistance arteries. Next, expression of signaling proteins and receptors is assessed using immunohistochemistry and mRNA analysis. Furthermore, the groups are compared with respect to levels of organic compounds that can influence the cardiovascular system (e.g. copeptin, (nor)epinephrine, ANP, BNP, NTproBNP, angiotensin II, cortisol, aldosterone, renin and VMA levels). During inclusion phase 2, only the ex vivo vascular reactivity test is performed in patients with (N = 12) and without heart failure (N = 12). Discussion: Understanding the difference in vascular responsiveness between patients with and without heart failure in detail, might yield therapeutic options or development of preventive strategies for vasoplegia, leading to safer surgical interventions and improvement in outcome. Trial registration: The Netherlands Trial Register (NTR), NTR5647. Registered 26 January 2016.

31 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
OPOlga Papazisi
Olga Papazisi
RPRudmer Postma
Rudmer Postma
RDRichard Dirven
Richard Dirven
SBSaskia L.M.A. Beeres
Saskia L.M.A. Beeres
RBRemco Berendsen
Remco Berendsen
AZAnton-Jan van Zonneveld
Anton-Jan van Zonneveld
Patients with heart failure with a reduced ejection fraction (HFrEF) are at an increased risk of developing postoperative hemodynamic instability and vasoplegia after surgery on cardiopulmonary bypass (CPB). Potentially pre-existing endothelial cell (EC) alterations due to chronic HF influence EC responses to cardiac surgery and might be responsible for the altered vascular responsiveness observed postoperatively. In this study, well-described EC activation markers were measured in blood samples collected pre- and perioperatively at four time points from HFrEF and control patients undergoing cardiac surgery on cardiopulmonary bypass (CPB). Circulating levels of Angiopoietin 2 (ANG2), von Willebrand Factor (vWF), and soluble P-selectin were measured using ELISA. Additionally, we investigated the responses of the cultured EC to patient-derived plasma through morphological profiling and mitochondrial functional assays. In total, 36 patients were included (67 (61–71) years, 78% male). HFrEF patients had higher baseline ANG2 and vWF levels when compared to controls. Both markers peaked during the first postoperative day. A pronounced increase in vWF was seen in controls after CPB. Ex vivo EC responses to patient-derived plasma showed distinct morphological differences between the two groups at baseline. A mitochondrial analysis indicated alterations in function and morphology for both groups after CPB. In conclusion, HFrEF patients exhibit a dampened EC response to cardiac surgery on CPB. Stable circulating factors in HFrEF plasma are responsible for inducing EC stress. Moreover, the mitochondrial function is highly affected postoperatively. This pre-existing mitochondrial and EC dysfunction predispose HFrEF patients to postoperative hemodynamic instability.

21 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OPOlga Papazisi
Olga Papazisi
MVMarieke van Vessem
Marieke van Vessem
SBSaskia L.M.A. Beeres
Saskia L.M.A. Beeres
Robert B. P. De WildeRobert B. P. De Wilde
Robert B. P. De Wilde
RBRemco Berendsen
Remco Berendsen
Meindert PalmenMeindert Palmen
Meindert Palmen
Background: Patients with chronic heart failure (HF) are at increased risk of vasoplegia after cardiac surgery, potentially because neurohormonal activation in the context of HF alters vascular regulation. Methods: We compared perioperative vasoresponsiveness in patients with and without HF undergoing cardiac surgery with cardiopulmonary bypass (CPB). Patients were prospectively enrolled, and changes in systemic vascular resistance (ΔSVR) after phenylephrine and nitroglycerin were measured perioperatively (in vivo). Ex vivo vasoreactivity to phenylephrine and vasopressin was tested in 40 biopsies. Results: In vivo and ex vivo analyses included 36 and 13 patients (10 controls and 3 HF patients), respectively. At baseline, phenylephrine increased SVR by 26% in HF patients (estimated marginal mean, 95% CI 16–35%) versus 51% in controls (95% CI 38–64%; p = 0.002). This attenuated response persisted during CPB, and ex vivo observations suggested a similar pattern. Responsiveness to nitroglycerin was unchanged. Lower post-CPB ΔSVR was associated with greater norepinephrine use during the first postoperative day (β = −346.6, 95% CI −541.2 to −151.9; R2 = 0.291). Conversely, HF patients showed greater ex vivo responsiveness to vasopressin. Conclusions: HF is associated with marked impairment of α1-adrenergic vasoresponsiveness, indicating impaired α1-adrenergic signaling. Preserved vasopressin responsiveness may support its earlier use for postoperative hypotension in these patients.